Image-guided tumor surgery: will there be a role for fluorescent nanoparticles?

Image‐guided surgery (IGS) using fluorescent nanoparticles (NPs) has the potential to substantially impact patient treatment. The use of fluorescence imaging provides surgeons with real‐time feedback on the location of diseased tissue using safe, low‐cost imaging agents and instrumentation. Fluoresc...

Full description

Saved in:
Bibliographic Details
Published in:Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2016-07, Vol.8 (4), p.498-511
Main Authors: Hill, Tanner K., Mohs, Aaron M.
Format: Article
Language:English
Subjects:
Cell surface
Chemical compounds
Clinical trials
Diagnostic software
Diagnostic systems
Drug discovery
Fluorescence
Fluorescent Dyes - therapeutic use
Fluorophores
Formulations
Humans
Imaging
Instrumentation
Medical personnel
Medical research
Methylene blue
Nanoparticles
Nanoparticles - therapeutic use
Nanotechnology
Neoplasms - surgery
Permeability
Proteins
Receptors
Surgery
Surgery, Computer-Assisted
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Image‐guided surgery (IGS) using fluorescent nanoparticles (NPs) has the potential to substantially impact patient treatment. The use of fluorescence imaging provides surgeons with real‐time feedback on the location of diseased tissue using safe, low‐cost imaging agents and instrumentation. Fluorescent NPs are likely to play a role as they are capable of taking advantage of the enhanced permeability and retention (EPR) effect and can be modified to avoid clearance, increase circulation time, and specifically target tumors. Clinical trials of IGS using the FDA‐approved fluorophores indocyanine green and methylene blue have already shown preliminary successes, and incorporation of fluorescent NPs will likely improve detection by providing higher signal to background ratio and reducing false‐positive rates through active targeting. Preclinical development of fluorescent NP formulations is advancing rapidly, with strategies ranging from passive targeting to active targeting of cell surface receptors, creating pH‐responsive NPs, and increasing cell uptake through cleavable proteins. This collective effort could lead to clinical trials using fluorescent NPs in the near future. WIREs Nanomed Nanobiotechnol 2016, 8:498–511. doi: 10.1002/wnan.1381 This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
ISSN:1939-5116
1939-0041
DOI:10.1002/wnan.1381